Scotiabank analyst Greg Harrison initiated coverage of Arcturus Therapeutics (ARCT) with an Outperform rating and $32 price target The shares are trading near the company’s cash position “with plenty of upside potential in the therapeutics pipeline,” the analyst tells investors in a research note. The firm believes Arcturus shares are “significantly undervalued” given the potential of the company’s therapeutics pipeline in cystic fibrosis and ornithine transcarbamylase deficiency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Earnings Call Highlights Progress and Challenges
- Arcturus Therapeutics price target lowered to $45 from $50 at Wells Fargo
- Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
- Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
- Arcturus Therapeutics price target lowered to $66 from $68 at Canaccord